Natco
-
{
- All
- News
- Videos
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Amid Caution, These Stocks Lose Upto 8% In Run Up To RBI Policy
Natco Pharma, Vakrangee, Redington, NTPC and HCL Technologies posted heavy losses on Wednesday.
-
Supreme Court's decision on Novartis AG to benefit poor patients, say pharma companies
Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic manufacturers.
-
Patent board rules against Bayer in cancer drug case
A patent appeals board upheld on Monday a decision to allow a domestic company to sell a generic version of Bayer AG's cancer drug Nexavar, in a blow for global drugmakers' efforts to hold on to monopolies on high-price medicines.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Amid Caution, These Stocks Lose Upto 8% In Run Up To RBI Policy
Natco Pharma, Vakrangee, Redington, NTPC and HCL Technologies posted heavy losses on Wednesday.
-
Supreme Court's decision on Novartis AG to benefit poor patients, say pharma companies
Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic manufacturers.
-
Patent board rules against Bayer in cancer drug case
A patent appeals board upheld on Monday a decision to allow a domestic company to sell a generic version of Bayer AG's cancer drug Nexavar, in a blow for global drugmakers' efforts to hold on to monopolies on high-price medicines.
